WuXi PharmaTech (Cayman), Inc., through its subsidiaries, operates as a pharmaceutical and biotechnology research and development outsourcing company in the People's Republic of China. It provides a portfolio of laboratory and manufacturing services in the drug discovery and development process to pharmaceutical and biotechnology companies. The company's services include discovery chemistry, such as lead generation, lead optimization, and synthetic chemistry; pharmaceutical development comprising formulation development for new chemical entities; and analytical services, including support of its laboratory and manufacturing services, as well as external services offered to customers. Its services also comprise service biology, such as assay development and compound screening; and drug metabolism and pharmacokinetic services, which involves in the analysis of how drug candidates act in the body over time, in vitro and in vivo absorption, disposition, metabolism and excretion, profiling, and metabolite identification. In addition, WuXi PharmaTech's services include process development, such as process research and process optimization services to assist customers to manufacture their drug candidates; and manufacturing of advanced intermediates, which are drug materials prior to refinement into active pharmaceutical ingredients. The company was founded in 2001 and is headquartered in Shanghai, the People's Republic of China.